Fairvalue-Calculator Fairvalue-Calculator
EN DE

Angelalign Technology Inc (AGLFF) Fair Value & Analysis

Healthcare · US · Market cap $1.5B

Price$8.77
Fair Value$3.33
Upside-62.0%
Quality94/100
Evidence: High Range $2.50 – $4.16

Analysis

Angelalign Technology Inc (AGLFF) currently trades at $8.77, while our model-based Fair Value estimate is $3.33 — implying the stock looks roughly 62.0% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Angelalign Technology Inc., an investment holding company, researches and designs, manufactures, sells, and markets clear aligner treatment solutions in the People's Republic of China and internationally. The company's products include Angel Aligner Pro and Angel Aligner Select, a custom made removable clear orthodontic aligners that move the patient's teeth into the proper position over time; Angel Aligner KiD, a early orthodontic solution from prevention to treatment; and Angel Aligner Retainer. It also provides orthodontics and cosmetic dentistry services, and other dental services through its dental clinics. In addition, it sells intraoral scanners, brackets, and other products to hospitals, dental clinics and distributors; and engages in investing activities. Angelalign Technology Inc. was founded in 2003 and is headquartered in Shanghai, China. Angelalign Technology Inc. is a subsidiary of CareCapital Orthotech Limited.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -61% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -38% Medline Inc (MDLN) -5% Becton, Dickinson and Company (BDX) -16% Alcon Inc (ALC) -44%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.